A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease (BeyoND)

A Multicenter, International, Open-label, Safety Study of ND0612, a Solution of Levodopa/Carbidopa Delivered Via a Pump System as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease

This is a multi-center, international, open-label, safety study of ND0612, a solution of levodopa/carbidopa (LD/CD) delivered via a pump system as a continuous SC infusion in subjects with advanced Parkinson's Disease (PD).

Study Overview

• Status: Active, not recruiting
• Conditions: Parkinson's Disease
• Intervention / Treatment: Drug: ND0612

Detailed Description

This is a multi-center, international, open-label, safety study of ND0612, a solution of LD/CD delivered via a pump system as a continuous SC infusion in subjects with advanced PD. Two cohorts of subjects are candidates for this study: subjects who completed treatment in study ND0612H-006 within one month prior to enrollment (Cohort 1) and ND0612 naïve subjects or subjects who completed treatment in a ND0612 clinical study more than one month before screening (Cohort 2). After screening procedures and confirmation of the inclusion/exclusion criteria, subjects and their study partners will be trained and assisted at their homes during the first week of treatment on the proper operation of the pump system. One mandatory home visit will be performed during the first week and then on a monthly basis during 12-months of treatment. Subjects will return for in-clinic visits at Week 1 and at Months 1, 2, 3, 4, 6, 9, and 12 for assessment of safety and efficacy variables. Subjects will be allowed to continue with study treatment for an optional treatment extension period of up to Month 102 and the clinic visits will be performed every 3 months to assess subject long-term safety. Safety follow-up visits will occur 1, 2, and 3 months after the last SC infusion of ND0612 or after early termination.

• Study Type: Interventional
• Enrollment (Actual): 214
• Phase: Phase 2

Contacts and Locations

Study Locations

• Austria
  • Innsbruck, Austria, 6020
    • Medical University Innsbruck
• Czechia
  • Chocen, Czechia, 565 01
    • NEUROHK, s.r.o.
  • Praha, Czechia, 100 00
    • CLINTRIAL s.r.o.
  • Rychnov nad Kněžnou, Czechia, 516 01
    • Vestra Clinics, s.r.o.
• France
  • Aix-en-Provence, France, 13616
    • Centre Hospitalier d'Aix
  • Amiens Cedex 1, France, 80054
    • CHU d'Amiens, Hopital Sud
  • BRON Cedex, France, 69677
    • Hopital Neurologique Pierre Wertheimer
  • Clermont-Ferrand Cedex 1, France, 63003
    • Hôpital Gabriel Montpied
  • Lille Cedex, France, 59037
    • Hôpital Roger Salengro
  • Marseille, France, 13385
    • Hôpital de la Timone
  • Poitiers, France, 86021
    • CHU De Poitiers
• Germany
  • Beelitz-Heilstätten, Germany, 14547
    • Kliniken Beelitz GmbH
  • Bochum, Germany, 44791
    • St. Josefs Hospital
  • Bremerhaven, Germany, 27574
    • Klinikum-Bremerhaven Reinkenheide
  • Dresden, Germany, 1307
    • Universitaetsklinikum Carl Gustav Carus an der Technischen Universitaet Dresden
  • Haag in Oberbayern, Germany, 83527
    • Klinik Haag
  • Ulm, Germany, 89081
    • Universitaets-und Rehabilitationskliniken Ulm
• Israel
  • Ashkelon, Israel, 7830604
    • Barzilai MC
  • Jerusalem, Israel, 91120
    • Hadassah Medical Center, Ein-Kerem Campus
  • Petah Tikva, Israel, 49100
    • Rabin Medical Center
  • Ramat Gan, Israel, 56520
    • Chaim Sheba Medical Center
  • Tel Aviv, Israel, 64239
    • Sourasky Medical Center
• Italy
  • Chieti, Italy, 66100
    • University Foundation
  • Pisa, Italy, 56126
    • AOU Pisa
  • Rome, Italy, 00163
    • IRCCS San Raffaele Pisana
  • Venice, Italy, 30126
    • IRCCS Hospital San Camillo Venice
• Poland
  • Kraków, Poland, 30-363
    • Centrum Medyczne Plejady
  • Kraków, Poland, 31-505
    • Krakowska Akademia Neurologii Sp. z o.o.
  • Lublin, Poland, 20-016
    • Indywidualna Praktyka Lekarska prof. dr hab
• Spain
  • Barcelona, Spain, 08036
    • Hospital Clinic de Barcelona
  • Madrid, Spain, 28006
    • Hospital Universitario de La Princesa
• United States
  • Arizona
    • Phoenix, Arizona, United States, 85004
      • Xenoscience
  • Arkansas
    • Little Rock, Arkansas, United States, 72205-6421
      • Clinical Trials Inc.
  • California
    • Fountain Valley, California, United States, 92708-5153
      • The Parkinsons and Movement Disorder Institute
    • Fresno, California, United States, 93710
      • Neuro Pain Medical Center
  • Colorado
    • Aurora, Colorado, United States, 80045
      • University of Colorado Denver
    • Englewood, Colorado, United States, 80113-2776
      • Rocky Mountain Movement Disorders Center
  • Florida
    • Boca Raton, Florida, United States, 33486-2359
      • Parkinson's Disease And Movement Disorder Center Of Boca Raton
    • Hallandale Beach, Florida, United States, 33009
      • MD Clinical
    • Hollywood, Florida, United States, 33021
      • Infinity Clinical Research, LLC
    • Jacksonville, Florida, United States, 32209
      • University of Florida Health at Jacksonville
    • Maitland, Florida, United States, 32751-4723
      • Neurology Associates, PA
    • Port Charlotte, Florida, United States, 33980
      • Parkinsons Disease Treatment Center of Southwest Florida
    • Saint Petersburg, Florida, United States, 33713-8844
      • Suncoast Neuroscience Associates
    • Sunrise, Florida, United States, 33351
      • Infinity Clinical Research, LLC
    • Tampa, Florida, United States, 33613
      • USF Health Parkinson's Disease and Movement Disorders
  • Illinois
    • Chicago, Illinois, United States, 60611
      • Northwestern University
  • Iowa
    • Des Moines, Iowa, United States, 50309
      • Unity Point Health
  • Maryland
    • Baltimore, Maryland, United States, 21201
      • University of Maryland, Neurology
  • Michigan
    • Farmington Hills, Michigan, United States, 48334
      • Quest Research Institute
    • West Bloomfield, Michigan, United States, 48322-3013
      • Henry Ford Hospital
  • New Jersey
    • Somerset, New Jersey, United States, 08873-3448
      • Pyramid Clinical Research
  • Ohio
    • Cincinnati, Ohio, United States, 45267
      • University of Cincinnati
  • Oklahoma
    • Tulsa, Oklahoma, United States, 74136
      • The Movement Disorder Clinic of Oklahoma
  • Virginia
    • Richmond, Virginia, United States, 23226
      • Synergy Trials
    • Virginia Beach, Virginia, United States, 23456-0168
      • Sentara Neuroscience Institute
  • Washington
    • Spokane, Washington, United States, 99202-1461
      • Premier Research

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 30 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

INCLUSION CRITERIA:

Cohort 1.

1. Subject is able to, and has signed an Institutional Review Board/Ethics Committee (IRB/EC)-approved informed consent form (ICF).
2. Subject has completed the treatment period of study ND0612H-006 not more than one month prior to enrolling in ND0612H-012.
3. Willing and able to administer the SC infusion alone or with the assistance of a study partner and able to comply with the study specific procedures.

Cohort 2.

1. Male and female PD subjects of any race aged at least 30 years who sign an IRB/EC-approved ICF.
2. PD diagnosis consistent with the UK Brain Bank Criteria.
3. Modified Hoehn & Yahr scale in "ON" state of stage ≤3.
4. Taking at least 4 doses/day of LD/DDI (or at least 3 doses/day of Rytary) and taking, or have attempted to take, at least one other PD treatment for at least 30 days.
5. Subjects must be stable on their anti-PD medications for at least 30 days before Day 1.
6. Subjects may have had prior exposure to SC apomorphine injections/infusion but must have stopped continuous apomorphine administration at least 4 weeks before the screening visit. Treatment with apomorphine is prohibited during the entire ND0612 treatment period.
7. Must have a minimum of 2 hrs of "OFF" time per day with predictable early morning "OFF" periods as estimated by the subject.
8. Must have predictable and well defined early morning "OFF" periods with a good response to LD for treatment of the early morning "OFF" in the judgement of the investigator.
9. Mini Mental State Examination (MMSE) score ≥26.
10. No clinically significant medical, psychiatric or laboratory abnormalities which the investigator judges would be unsafe or non-compliant in the study.
11. Female subjects must be surgically sterile (hysterectomy, bilateral oophorectomy, or tubal ligation), postmenopausal (defined as cessation of menses for at least 1 year), or willing to practice a highly effective method of contraception. All female participants must be non-lactating and non-pregnant and have a negative urine pregnancy test at Screening and at Baseline. Female subjects of childbearing potential must practice a highly effective method of contraception (e.g., oral contraceptives, intrauterine devices, partner with vasectomy), 1 month before enrollment, for the duration of the study, and 3 months after the last dose of study drug. Alternatively, true abstinence is acceptable when it is in line with the subject's preferred and usual lifestyle. If a subject is usually not sexually active but becomes active, the subject and sexual partner must comply with the contraceptive requirements detailed above.
12. Willing and able to administer the SC infusion alone or with the assistance of a study partner after a screening period of up to 40 days and willing and able to comply with study requirements.
13. Subjects should have a named study partner.

EXCLUSION CRITERIA:

Cohort 1 and 2. Previously unable to tolerate ND0612 and/or have experienced intolerable adverse drug reactions associated with its use, regardless of the dosing regimen administered.

Cohort 2.

1. Atypical or secondary parkinsonism.
2. Acute psychosis or hallucinations in past 6 months.
3. Any relevant medical, surgical, or psychiatric condition, laboratory value, or concomitant medication which, in the opinion of the Investigator makes the subject unsuitable for study entry or potentially unable to complete all aspects of the study.
4. Any malignancy in the 5 years prior to randomization (excluding basal cell carcinoma of the skin or cervical carcinoma in situ that have been successfully treated).
5. Positive serum serology for Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or Human Immunodeficiency Virus (HIV) at the Screening visit.
6. Prior neurosurgical procedure for PD, or Duodopa treatment
7. Subjects with a history of drug abuse or alcoholism within the past 12 months.
8. Clinically significant ECG rhythm abnormalities.
9. Renal or liver dysfunction that may alter drug metabolism including: serum creatinine >1.3 mg/dL, serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2 x upper limit of normal (ULN), total serum bilirubin >2.5 mg/dL.
10. Current participation in a clinical trial with an investigational product or past participation within the last 30 days before Day 1.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 24-hour dosing regimen; Continuous SC infusion over 24 hours: fixed day rate of up to 0.64 mL/h for 18 hours, followed by a night rate of 0.08 mL/h for 6 hours to deliver a total daily dose of up to 720/90 mg of levodopa/carbidopa. All patients who had been previously assigned to the 24-hour group in the prior study continued on this dosing regimen; patients who had previously been assigned to the 14-hour daytime regimen were switched to the 24-hour regimen.	Drug: ND0612; ND0612, a solution of levodopa/carbidopa (LD/CD) delivered continuously subcutaneously (SC) via an infusion pump system; Other Names: ND0612H
Experimental: 16-hour dosing regimen; Continuous SC infusion for over 16 hours: fixed rate of 0.75 mL/h to deliver a total infusion dose of 720/90 mg of levodopa/carbidopa over 16 hours. The device is removed at night and patients in this group also receive a morning oral dose of levodopa/carbidopa upon awakening.	Drug: ND0612; ND0612, a solution of levodopa/carbidopa (LD/CD) delivered continuously subcutaneously (SC) via an infusion pump system; Other Names: ND0612H

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse Events (Long-term Safety)	Long-term safety (systemic and local) assessment will be based on adverse events (AEs), with a focus on adverse events of special interest (AESI), i.e., infusion site reactions, cases of hypersensitivity, polyneuropathy.	Baseline to Month 12
Percentages of Subjects Who Complete the 12-month Treatment Period or Discontinue Due to AE (Tolerability)	Tolerability will be assessed based on the percentage of subjects that complete the 12-month treatment period of the study and the percentage of subjects who discontinue from the 12-month treatment period due to an AE.	Baseline to Month 12

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse Events (Long-term Safety)	Long-term safety (systemic and local) and tolerability will be based on AEs, with a focus on AESI, i.e., infusion site reactions, cases of hypersensitivity, polyneuropathy.	Month 12 to Month 102

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change of Daily "ON" Time Without Troublesome Dyskinesia	Exploratory endpoint. "ON" time without troublesome dyskinesia is defined as the sum of "ON" time without dyskinesia and "ON" time with non-troublesome dyskinesia. Daily "ON" time without troublesome dyskinesia will be assessed based on home "ON/OFF" diaries and normalized to 16 hours of awake time.	Baseline to Month 12
Change of Daily "OFF" Time	Exploratory endpoint. Daily "OFF" time will be assessed based on home "ON/OFF" diaries and normalized to 16 hours of awake time.	Baseline to Month 12
Change of Total Daily Dose of Oral LD/DDI	Exploratory endpoint. Total daily dose of oral Levodopa (LD)/Dopa-Decarboxylase Inhibitor (DDI).	Baseline to Month 12
Proportion of Responders	Exploratory endpoint. A responder is defined as a subject that experiences ≥50% reduction in "OFF" time from Baseline. Improvement of ≥50% in "OFF" time will be assessed based on home "ON/OFF" diaries and normalized to 16 hours of awake time.	Baseline to Month 12
Change of Daily "ON" Time With Troublesome Dyskinesia	Exploratory endpoint. Daily "ON" time with troublesome dyskinesia will be assessed based on home "ON/OFF" diaries in a subset of subjects who had more than 1 hour of troublesome dyskinesia at baseline. It will be normalized to 16 hours of awake time.	Baseline to Month 12
Change of PDQ-39 Scores	Exploratory endpoint. Quality of Life in Parkinson's Disease (PDQ)-39 is a 39-item, self-administered questionnaire with 8 discrete dimensions (mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort.). The PDQ-39 Summary Index is the sum of the dimension scores divided by the number of dimensions. Higher scores indicate a worse quality of life.	Baseline to Month 12
Change of EQ-5D-5L Scores	Exploratory endpoint. The perception of general quality of life (QoL) will be rated by the subjects using the EuroQoL 5-dimensions 5-severity levels (EQ-5D-5L) questionnaire. The EQ-5D-5L consists of 2 pages, the EQ-5D-5L descriptive system and the EQ Visual Analogue Scale (VAS). The descriptive system comprises 5 dimensions (mobility, self care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The EQ VAS records the respondent's self-rated health on a 20 cm vertical VAS with endpoints labelled 'the best health you can imagine' and 'the worst health you can imagine'. Decrease in the 5-dimensions scores and increase in EQ VAS score will indicate improvement.	Baseline to Month 12
Change of UPDRS Part II (ADL)	Exploratory endpoint. The Unified Parkinson's disease rating scale (UPDRS) is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS Part II (activity of daily living) score was calculated as the sum of the individual UPDRS items 5-17. The Part II score is the sum of the answers to the 13 questions that comprise Part II, each of which are measured on a 5-point scale (i.e., 0 is normal and 4 indicates a severe abnormality). Higher scores correlate with greater impairments for daily activities.	Baseline to Month 12
Change in CGI-Severity and CGI-Improvement	Exploratory endpoint. Clinical Global Impression (CGI) Severity (CGI-S) and Improvement (CGI-I) are rated by the investigator or designee. CGI-S employs a 7-point scale with 1 being "not at all ill" and 7 being "among the most severely ill subjects" for severity rating. The CGI-I employs a 7-point scale with 1 being "very much improved" and 7 being "very much worse" for improvement rating.	Baseline to Month 12
Change in SGI-Improvement	Exploratory endpoint. Subjects Global Impression of Improvement (SGI-I) is rated by the subject. The SGI-I employs a 7-point scale with 1 being "very much improved" and 7 being "very much worse" for improvement rating.	Baseline to Month 12
Change in PDSS-2 Total Score	Exploratory endpoint. The quality of night sleep is rated by the subjects using the Parkinson's Disease Sleep Scale (PDSS)-2, which includes questions addressing 15 commonly reported symptoms associated with sleep disturbance in PD. Higher scores indicate a lower quality of sleep, i.e., a reduction in the score indicates an improvement in sleep quality.	Baseline to Month 12
Change in UPDRS Part III (Motor Score)	Exploratory endpoint. The Unified Parkinson's Disease Rating Scale (UPDRS) is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. UPDRS part III (motor) score is calculated as the sum of the individual UPDRS items 18-31, each of which are measured on a 5-point scale (i.e., 0 is normal and 4 indicates a severe abnormality). Higher scores correlate with greater motor impairment.	Baseline to Month 12
Change in Percentage of "OFF" Time and Percentage of Good "ON" During the First 3 Hours Since the Subject is Awake After 06:00 (6 am)	Exploratory endpoint. Good "ON" time (or "ON" time without troublesome dyskinesia) is defined as the sum of "ON" time without dyskinesia and "ON" time with non-troublesome dyskinesia. For this endpoint, Good "ON" time and "OFF" time will be assessed based on home "ON/OFF" diaries during the first 3 hours since the subject is awake after 06:00 (6 am).	Baseline to Month 12
Change in ND0612 Total Dose	Exploratory endpoint. Change in ND0612 total daily dose.	Baseline to Month 12
Proportion of Patients Who Reduced ND0612 Total Dose	Exploratory endpoint. Proportion of patients who reduced ND0612 total dose at any time during the study.	Baseline to Month 102

Collaborators and Investigators

• Sponsor: NeuroDerm Ltd.
• Investigators: Study Director: Laurence Salin, MD, NeuroDerm Ltd.

Publications and helpful links

General Publications

• Poewe W, Stocchi F, Arkadir D, Ebersbach G, Ellenbogen AL, Giladi N, Isaacson SH, Kieburtz K, LeWitt P, Olanow CW, Simuni T, Thomas A, Zlotogorski A, Adar L, Case R, Oren S, Fuchs Orenbach S, Rosenfeld O, Sasson N, Yardeni T, Espay AJ; BeyoND study group. Subcutaneous Levodopa Infusion for Parkinson's Disease: 1-Year Data from the Open-Label BeyoND Study. Mov Disord. 2021 Nov;36(11):2687-2692. doi: 10.1002/mds.28758. Epub 2021 Sep 8.

Study record dates

Study Major Dates

• Study Start (Actual): May 4, 2016
• Primary Completion (Actual): September 9, 2019
• Study Completion (Estimated): February 1, 2027

Study Registration Dates

• First Submitted: March 29, 2016
• First Submitted That Met QC Criteria: March 31, 2016
• First Posted (Estimated): April 1, 2016

Study Record Updates

• Last Update Posted (Actual): May 30, 2025
• Last Update Submitted That Met QC Criteria: May 20, 2025
• Last Verified: May 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Synucleinopathies; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurodegenerative Diseases; Movement Disorders; Parkinsonian Disorders; Basal Ganglia Diseases; Parkinson Disease
• Other Study ID Numbers: ND0612H-012